Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
1.415 Leser
Artikel bewerten:
(2)

Phoenix Life Sciences International Limited: Letter of Intent for Merger Between Phoenix Life Sciences and ArCare Holdings Sdn Bhd

LAS VEGAS, NV / ACCESSWIRE / December 24, 2021 / Phoenix Life Sciences International Limited, ("PLSI") (OTC PINK:PLSI) a publicly-traded company, is pleased to announce that a letter of intent ("LOI") for a reorganization and merger between PLSI and ArCare Holdings Sdn Bhd has been executed and the merger closing is expected in Q1 2022. ArCare Holdings Sdn Bhd ("ArCare") is a privately held technology company developing Electronic Healthcare Benefits delivery and management.

ArCare (www.arcarehmo.com) intends to become a dominant provider of Electronic Healthcare Delivery and Benefits Management in Southeast Asia and beyond. ArCare Holdings Sdn Bhd is registered with the Ministry of Health Malaysia as a Managed Care Organization, structured to manage the healthcare needs of corporate employees and individual subscribers through the use of the latest in mHealth technology and the efficient management of available resources. ArCare's value proposition is in delivering enhanced patient outcomes and experiences, greater professional satisfaction for providers and caregivers and lower care costs.

Following the merger, the company formerly known as PLSI will be known as ArCare.

PLSI ceased operations following legal settlements announced in late 2020. Through the merger and reorganization, the board of directors will be replaced and all existing directors and officers shall resign. PLSI will become Phoenix Dissolution Corporation and will be a discontinued business venture.

Dr. Jeevan Muthiah, CEO of ArCare, said, "The merger between PLSI and ArCare will enable us to leverage our technology with the increased visibility of the public market." Further, Dr. Muthiah, stated "We look forward to gaining greater access to capital markets and to commencing the expansion of the suite of products. We believe this transaction will enable ArCare to grow rapidly and capture market share in our initial target markets."

About ArCare

ArCare, a Managed Care Organization, works collaboratively with physicians, care teams and practices on their transition from traditional fee-for-service to value-based care. ArCare's value proposition is in delivering enhanced patient outcomes and experiences, greater professional satisfaction for providers and caregivers and lowering care costs both to patients and insurers.

For more information on ArCare see www.arcarehmo.com

ArCare is a subsidiary under its holding company Archipelago Associates Limited (AAL), a leading Technology and Digitalization enabler focused on bringing value to ecosystems in Health and Agriculture. (www.exploreaal.com).

Forward-Looking Statements

Information contained in this press release regarding ArCare and PLSI (the "Companies") may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Companies actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in PLSI's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.

PLSI Investor Contact:
investor.relations@plsi.co
www.plsi.co
+1.844.329.0895

SOURCE: Phoenix Life Sciences International Limited



View source version on accesswire.com:
https://www.accesswire.com/679549/Letter-of-Intent-for-Merger-Between-Phoenix-Life-Sciences-and-ArCare-Holdings-Sdn-Bhd

© 2021 ACCESS Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.